Sirukumab
Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6 (IL-6). Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor Clinical trials. Rheumatoid arthritis. It has started clinical trials. and reported some phase II results. In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data. By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints. Other. The drug is currently in phase II clinical trials for the treatment of depression. Sirukumab